Diagnosing and treating opioid dependence

,; ,; ,; ,

Applied Evidence

Diagnosing and treating opioid dependence

J Fam Pract. 2012 October;61(10):588-597

By

Kevin P. Hill, MD, MHS

Lindsay S. Rice, BA

Hilary S. Connery, MD, PhD

Roger D. Weiss, MD

The surge in opioid abuse highlights the importance of questioning patients about their use of prescription analgesics—and knowing when and how to intervene.

PDF Download

References

1. Centers for Disease Control and Prevention (CDC). Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010;59:705-709.

2. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315-1321.

3. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief. 2009;(22):1-8.4.

4. Substance Abuse and Mental Health Services Administration. Results From the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Rockville, Md: SAMHSA, Office of Applied Studies; 2010. NSDUH Series H-38A, HHS publication SMA 10-4856. Available at: http://www.samhsa.gov/data/NSDUH/2k9NSDUH/2k9Results.htm. Accessed August 22, 2012.

5. Hser YI, Huang D, Brecht ML, et al. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis. 2008;27:13-21.

6. Veilleux JC, Colvin PJ, Anderson J, et al. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2011;30:155-166.

7. George O, Koob GF. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2011;35:232-247.

8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev (DSM-IV-TR). Arlington, Va: American Psychiatric Association; 2000.

9. American Psychiatric Association. R 19 opioid use disorder. http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=460. Updated April 30, 2012. Accessed June 20, 2012.

10. Substance Abuse and Mental Health Services Administration. Results From the 2008 National Survey on Drug Use and Health: National Findings. Rockville, Md: SAMHSA, Office of Applied Studies; 2009. NSDUH Series H-36, HHS publication SMA 09-4434. Available at: http://www.samhsa.gov/data/nsduh/2k8nsduh/2k8Results.htm. Accessed August 22, 2012.

11. Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J. 1995;94:135-140.

12. Skinner HA. The drug abuse screening test. Addict Behav. 1982;7:363-371.

13. US Preventive Services Task Force. Screening for Illicit Drug Use: U.S. Preventive Services Task Force Recommendation Statement. January 2008. Available at: http://www.uspreventiveservicestaskforce.org/uspstf08/druguse/drugrs.htm. Accessed May 7, 2012.

14. Gourlay D, Caplan Y, Heit H. Urine Drug Testing in Clinical Practice: Dispelling the Myths and Designing Strategies. San Francisco, Calif: California Academy of Family Physicians; 2006.

15. Jackman R, Purvis J, Mallett B. Chronic nonmalignant pain in primary care. Am Fam Physician. 2008;78:1155-1162.

16. McBane S, Weigle N. Is it time to drug test your chronic pain patient? J Fam Pract. 2010;59:628-633.

17. Madras BK, Compton WM, Avula D, et al. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99:280-295.

18. The InSight Project Research Group. SBIRT outcomes in Houston: final report on InSight, a hospital district-based program for patients at risk for alcohol or drug use problems. Alcohol Clin Exp Res. 2009;33:1374-1381.

19. Borges G, Walters EE, Kessler RC. Associations of substance use, abuse, and dependence with subsequent suicidal behavior. Am J Epidemiol. 2000;151:781-789.

20. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51:390-395.

21. Smedslund G, Berg RC, Hammerstrom KT, et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 2011;(5):CD008063.-

22. Gryczynski J, Mitchell SG, Peterson TR, et al. The relationship between services delivered and substance use outcomes in New Mexico’s Screening, Brief Intervention, Referral and Treatment (SBIRT) Initiative. Drug Alcohol Depend. 2011;118:152-157.

23. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300:2003-2011.

24. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68:1238-1246.

25. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101:491-503.

26. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300:2613-2620.

27. Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003;69:215-232.

28. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. Res Publ Assoc Res Nerv Ment Dis. 1992;70:205-230.

29. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.-

30. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19:4-16.

31. Office of National Drug Control Policy Reauthorization Act of 2006 (ONDCPRA), HR 6344, 109th Cong, 2nd Sess (2006).

32. Lewis JW, Walter D. Buprenorphine—background to its development as a treatment for opiate dependence. In: Blaine JD, ed. Buprenorphine: An Alternative Treatment for Opioid Dependence. Rockville, Md: National Institute on Drug Abuse; 1992:5-11. NIDA Research Monograph, No. 121. Available at: http://archives.drugabuse.gov/pdf/monographs/121.pdf. Accessed August 22, 2012.

33. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-580.

34. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88:75-78.

35. Hallinan R, Byrne A, Agho K, et al. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5:684-692.

36. Rapeli P, Fabritius C, Alho H, et al. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol. 2007;7:5.-

37. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167:2469-2475.

38. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, Md: Substance Abuse and Mental Health Services Administration; 2004. Treatment Improvement Protocol (TIP) Series 40. DHHS publication SMA 04-3939.

39. Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300:2303-2305.

40. Hulse GK, Morris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66:1108-1115.

41. US Food and Drug Administration. FDA approves injectable drug to treat opioid-dependent patients. October 12, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm229109.htm. Accessed September 11, 2012.

42. Inturrisi CE, Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther. 1972;13 (5 pt 1):633-637.

43. Stitzer M, Bigelow G, Lawrence C, et al. Medication take-home as a reinforcer in a methadone maintenance program. Addict Behav. 1977;2:9-14.

44. Code of Federal Regulations. Title 42.8.12. Federal Opioid Treatment Standards. October 2010.

45. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290-1297.

46. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387-395.

47. Ball JC, Lange WR, Myers CP, et al. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988;29:214-226.

48. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365-374.

49. Defulio A, Everly JJ, Leoutsakos JM, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend. 2012;120:48-54.

50. Savage SR. Management of opioid medications in patients with chronic pain and risk of substance misuse. Curr Psychiatry Rep. 2009;11:377-384.

PRACTICE RECOMMENDATIONS

• Ask all patients about the inappropriate use of substances, including prescription opioids. A

• Recommend pharmacotherapy for patients entering treatment for opioid dependence. A

• Warn patients who are opioid dependent about the risk of accidental fatal overdose, particularly with relapse. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE Sam M, age 48, is in your office for the first time in more than 2 years. He has gained a considerable amount of weight and appears a bit sluggish, and you wonder whether he’s depressed. While taking a history, Sam reminds you that he was laid off 16 months ago and had been caring for his wife, who sustained a debilitating back injury. When you saw her recently, she told you she’s back to work and pain-free. So you’re taken aback when Sam asks you to refill his wife’s oxycodone prescription for lingering pain that often keeps her up at night.
If Sam were your patient, would you suspect opioid dependence?

Dependence on opioid analgesics and the adverse consequences associated with it have steadily increased during the past decade. Consider the following:

Between 2004 and 2008, the number of emergency department visits related to nonmedical prescription opioid use more than doubled, rising by 111%.¹
The increasing prevalence of opioid abuse has led to a recent spike in unintentional deaths,² with the number of lives lost to opioid analgesic overdose now exceeding that of heroin or cocaine.³
More than 75% of opioids used for nonmedical purposes were prescribed for someone else.⁴

FAST TRACK

Rapid progression from misuse of opioids to dependence is most common in vulnerable populations, such as those with concurrent mental illness, another substance use disorder, or increased sensitivity to pain.

The course of opioid use is highly variable. Some people start with a legitimate medical prescription for an opioid analgesic, then continue taking it after the pain subsides. Others experiment briefly with nonmedical prescription opioids or use them intermittently without adverse effect. Some progress from prescription opioids to heroin, despite its dangers.⁵ Still others have a catastrophic outcome, such as an overdose or severe accident, the first time they use opioids.⁶ Rapid progression from misuse of opioids to dependence is most likely in vulnerable populations, such as those with concurrent mental illness, other substance use disorders, or increased sensitivity to pain.⁷

Understanding the terms. Before we continue, a word about terminology is in order. “Misuse” generally refers to the use of a medication in a manner (ie, purpose, dose, or frequency) other than its intended use, while “drug addiction” is the repeated use of a drug despite resulting harm. Here we will use “opioid dependence” to mean a pattern of increasing use characterized by significant impairment and distress and an inability to stop, and “opioid withdrawal” to reflect a constellation of symptoms, such as insomnia, nausea, diarrhea, and muscle aches, that can follow physiological dependence (though not necessarily opioid dependence). Our definitions of these terms are consistent with those of the American Psychiatric Association (APA).⁸ Worth noting, however, is the fact that as the APA prepares for the publication of the 5th edition of its Diagnostic and Statistical Manual of Mental Disorders, its Substance Disorder Work Group has proposed replacing the term “opioid dependence” with “opioid use disorder” to reduce the confusion associated with these definitions.⁹

Assessing illicit opioid use: Start with a targeted question

Most patients who are opioid dependent do not seek treatment for it,¹⁰ and are typically free of medical sequelae associated with drug addiction when they see family practitioners. The absence of self-reporting and obvious physical signs and symptoms, coupled with the increase in illicit use of prescription opioids, underscores the need for family physicians to identify patients who are abusing opioids and ensure that they get the help they need.

Screening tools. There are a number of screening tools you can use for this purpose—eg, CAGE-Adapted to Include Drugs (CAGE-AID) and Drug Abuse Screening Test (DAST)^11,12—but they have not been found to be significantly better than a careful substance abuse history.¹³

Straightforward questions. You can start by asking, “Do you take any medications for pain?” If the answer is Yes, get the name of the drug and inquire about the frequency of use and the route, the amount typically taken, and the duration of the current use pattern. Ask specifically about opioids when taking a substance abuse history. After a question about alcohol use, you can say, “Do you use any other drugs in a serious way? Marijuana? Opioids like Percocet, Vicodin, or Oxycontin?” Although it can be very difficult to detect opioid dependence if the patient is not forthcoming, other likely indicators of drug-seeking behavior should trigger additional questions. (See “Opioid dependence: Red flags to keep in mind”.^14-16)